Global Flu RNA Vaccines Market By Product (Non-replicating mRNA, In vivo self-replicating mRNA, In Vitro Dendritic Cell Non-replicating mRNA Vaccine), By Route of Administration(Injections, Nasal Sprays, Based on Age Group:, Pediatrics, Adults), By Distribution Channels (Hospitals, Vaccination Centers, Specialized Clinics, Hospital Pharmacies), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2031
- Published date: Jan 2022
- Report ID: 73936
- Number of Pages: 312
- Format:
- keyboard_arrow_up
Antibodies created due to influenza (flu) vaccinations develop in the body two weeks after immunization. These antibodies protect against infection from viruses that are used to produce a vaccine. According to a study, the seasonal flu vaccine protects against influenza viruses that are predicted to be the most common over the coming season.
RNA vaccines can be administered by a variety of routes, including needle syringe injections into the skin, directly into bloodstream, lymph, and organs; it can even be administered via nasal spray. RNA-based vaccines are generally relatively quick and affordable to manufacture, they may be safer to administer and may herald a more rapid control of infectious diseases including influenza, COVID-19, etc.
The main benefit of RNA vaccines is that they do not require the use of live cells in the vaccine preparation process. Instead, these vaccines can be manufactured in the lab using a DNA template with readily available materials, making them a simple and quick weapon to combat new outbreaks and existing infectious diseases.
Detailed Segmentation –
The global flu RNA vaccines market is segmented on the basis of – Product Types, Route of Administration, Age Group, Distribution Channels, and Region. Represented below is a detailed segmental description:
Based on Product Types:
- Non-replicating mRNA
- In vivo self-replicating mRNA
- In Vitro Dendritic Cell Non-replicating mRNA Vaccine
Based on Route of Administration:
- Injections
- Nasal Sprays
Based on Age Group:
- Pediatrics
- Adults
Based on Distribution Channels:
- Hospitals
- Vaccination Centers
- Specialized Clinics
- Hospital Pharmacies
Based on Region
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Market Dynamics –
Drivers for the Global Flu RNA Vaccines Market:
RNA vaccines have a number of advantages, including a simple production procedure that allows them to be manufactured faster than other vaccinations. In this pandemic, RNA vaccines can be prepared in about eight days. Even if flu virus strains change from year-to-year, the manufacturing method remains the same. This factor is expected to boost the economic growth of this market.
During the COVID-19 pandemic, this market increased at an astonishing rate because of the augmented demand for flu vaccines across all locations that were impacted by this pandemic. As a result, the COVID-19 pandemic has had a favorable impact on this market.
Opportunities for the Global Flu RNA Vaccines Market:
Existing industry players are focusing on innovation and finding efficient Flu RNA vaccines, as well as missing elements in technologies that may help to manufacture these vaccines at a more rapid pace. These factors are expected to create lucrative opportunities for this market.
Competitive Landscape –
Key players in this market are – Sanofi Pasteur Inc. (Sanofi S/A), AstraZeneca Plc, CSL Ltd. (Seqirus), Abbott Laboratories, GlaxoSmithKline Plc, Serum Institute of India Pvt. Ltd., Pfizer Inc., BioNTech SE, F. Hoffman La Roche Ltd., Novartis International AG, Sinnovac Biotech Ltd., Moderna Inc., and CureVac N.V., among others. These key industry players are now focusing on mergers, partnerships, acquisitions, product developments, and collaboration strategies, in order to sustain their respective competitive edges.
Key Developments –
- Pfizer has recently entered into a collaboration with German biotech company BioNTech to develop new RNA vaccine technology to create a better flu shot.
For the Flu RNA Vaccines Market research study, the following years have been considered to estimate the market size:
Attribute Report Details Historical Years
2016-2020
Base Year
2021
Estimated Year
2022
Short Term Projection Year
2028
Projected Year
2023
Long Term Projection Year
2032
Report Coverage
Competitive Landscape, Revenue analysis, Company Share Analysis, Manufacturers Analysis, Volume by Manufacturers, Key Segments, Key company analysis, Market Trends, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis, strategy for existing players to grab maximum market share, and more.
Regional Scope
North America, Europe, Asia-Pacific, South America, Middle East & Africa
Country Scope
United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa
- Sanofi Pasteur Inc. (Sanofi S/A)
- AstraZeneca Plc Company Profile
- CSL Ltd. (Seqirus)
- Abbott Laboratories
- GlaxoSmithKline Plc
- Serum Institute of India Pvt. Ltd.
- Pfizer Inc Company Profile
- BioNTech SE
- F. Hoffman La Roche Ltd.
- Novartis AG Company Profile
- Sinnovac Biotech Ltd.
- Moderna Inc.
- CureVac N.V.
- others
- settingsSettings
Our Clients
Single User
$5,999
$2,999
USD / per unit
save 50% |
Multi User
$7,999
$3,499
USD / per unit
save 55% |
Corporate User
$12,999
$4,499
USD / per unit
save 65% | |
---|---|---|---|
e-Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 2,999) | Buy Now ($ 3,499) | Buy Now ($ 4,499) |